多发性硬化症与其他慢性炎症疾病的并发症的治疗选择
Deutsches Arzteblatt international
|June 17, 2025
概括
治疗多发性硬化症 (MS) 和并发性慢性炎症疾病需要个性化,跨学科的护理. 根据疾病的严重程度和类型,建议使用特定疗法,如二甲基烟酸盐,阿扎西奥普林和抗CD20抗体.
科学领域:
- 神经学 神经学
- 免疫学 免疫学 免疫学
- 皮肤病学 皮肤病学
- 类风湿病学 类风湿病学
- 胃肠病学 胃肠病学
背景情况:
- 多发性硬化症 (MS) 在德国影响大约28万个人.
- 大约5%的MS患者同时患有慢性炎症性疾病,如牛皮,类风湿性关节炎 (RA) 或炎症性肠病 (IBD).
研究的目的:
- 为管理MS和其他慢性炎症疾病患者提供专家共识.
- 审查这些复杂病例的当前治疗选择和建议.
主要方法:
- 一个基于PubMed文献搜索和相关临床指南的叙事评论.
- 由来自各种医学学科的作者开发的共识陈述.
主要成果:
- 由于潜在的疾病恶化,TNFα抑制剂通常在MS患者中是禁忌的.
- 对于患有牛皮的轻度多发性硬化症,二甲基烟酸是可行的选择.
- 对于RA的MS,阿扎西奥普林或莱夫卢诺胺/特里夫卢诺胺适用于轻度活性;抗CD20抗体建议用于严重活性.
- 对于患有IBD的MS,阿扎西奥普林适用于轻度活性;Ozanimod被批准用于JC阴性患者的严重性结肠炎.
结论:
- 患有多发性硬化和并发性慢性炎症疾病的患者的治疗需要跨学科和个性化的方法.
- 仔细考虑潜在的不良影响至关重要.
- 对这种患者群体的最佳治疗策略需要进一步研究.
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
278
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
278
Inflammatory Bowel Disease IV: Pharmacological Management
205
Upon diagnosis, managing Inflammatory Bowel Disease (IBD) involves addressing several crucial aspects. The primary goals include resting the bowel, correcting malnutrition, and providing symptomatic relief. Resting the bowel may consist of medications to reduce inflammation and promote healing. Correcting malnutrition is essential, often requiring dietary adjustments and nutritional supplements. Symptomatic relief aims to ease pain, diarrhea, and other discomforts in IBD.
Pharmacologic...
Pharmacologic...
205
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
212
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2...
212
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
240
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab...
240
Autoimmune Disorders
685
Autoimmune diseases are a group of disorders in which the body's immune system mistakenly attacks its own cells, tissues, and organs. This results from an overactive immune response against substances and tissues normally present in the body. Let's delve into the concept and mechanism of autoimmune diseases from an immune system point of view, explore different causes and examples of such diseases, and discuss potential solutions.
Concept and Mechanism of Autoimmune Diseases
The immune...
Concept and Mechanism of Autoimmune Diseases
The immune...
685
Drugs for Treatment of Ulcerative Colitis in IBD
244
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
244


